Solid Tumors
Conditions
Brief summary
This study is an open-label, single-arm clinical trial to evaluate the safety, pharmacokinetics, and preliminary efficacy of GK01 in patients with advanced solid tumors.
Interventions
DRUGGK01 Injection
Autologous tumor-reactive T cells injection
Sponsors
Tianjin Medical University Cancer Institute and Hospital
Beijing Geekgene Technology Co., LTD
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Ability to understand and sign a written informed consent document. * At the date of signing ICF, 18 \~70 years old, male or female. * Patients with solid tumors confirmed by histopathology (including but not limited to pancreatic cancer, cholangiocarcinoma, gastric cancer, etc.) who are judged by investigator to be capable of undergoing radical total resection of the primary tumor for the purpose of cure. * No treatment for the primary tumor was received before surgical resection (no induction therapy or recurrent disease). * The expected survival time is more than 12 weeks;. * ECOG 0-1 points.
Exclusion criteria
* Inoperable or metastatic (Stage IV) solid tumors. * Central nervous system (CNS) metastasis, leptomeningeal disease, or metastatic spinal cord compression; or a history of CNS disorders, including but not limited to epilepsy, paralysis, aphasia, stroke, severe brain injury, dementia, Parkinson's disease, etc. * History of bone marrow or solid organ transplantation. * History of other primary malignancies within 5 years prior to study treatment * Hepatitis B surface antigen (HBsAg) positivity; With negative HBsAg but positive hepatitis B core antibody (HBcAb) ,and if peripheral blood hepatitis B virus (HBV) DNA positive; Hepatitis C virus (HCV) antibody positive and HCV RNA positive; Human immunodeficiency virus (HIV) antibody positive; Cytomegalovirus (CMV) DNA positive; Both Treponema pallidum-specific and non-specific antibody tests are positive. * Allergy to any components of the drugs planned. * Previous radiotherapy within 28 days before signing the ICF. * History of active tuberculosis infection within 1 year before screening. * Concurrent or previous history of interstitial lung disease or interstitial pneumonia; presence of chronic lung disease or other respiratory conditions that significantly impair lung function. * Diagnosis of active autoimmune disease or a history of autoimmune disease that may recur (e.g., systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vasculitis, psoriasis, etc.), or at risk of such conditions. * Investigator-assessed clinically significant thyroid dysfunction. * Cardiovascular diseases with clinical significance. * No contraindications to curative resection of the primary tumor. * Attenuated or inactivated vaccines within 28 days before signing the I form, or planned administration of such vaccines during the screening period. * Comorbidities or other conditions are likely to affect protocol compliance or suitability for participation in this study. * Female subjects who are pregnant or breastfeeding.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Safety and Tolerability | 2 years | The incidence and severity, and correlation of AEs (Adverse Events) and SAEs (Serious Adverse Events). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| PK | 2 years | Levels of T-cell Receptor copies |
| Recurrence free survival(RFS) | 2 years | RFS will will be assessed from radical surgery to death of any cause (evaluated according to the RECIST criteria). |
| Overall survival (OS ) | 2 years | OS will be assessed from the first GK01 infusion to death from any cause (Assessed based on RECIST criteria) |
| Patient Quality of Life | 2 years | EORTC(European Organisation for Research and Treatment of Cancer) QLG (Quality of Life Group)Core Questionnaire (EORTC QLQ-C30) |
| PD marker | 2 years | Concentration levels of serum cytokines, tumor markers and other related markers. |
Countries
China
Contacts
CONTACTJihui Hao
Outcome results
None listed